INT20981

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.48
First Reported 1990
Last Reported 2010
Negated 2
Speculated 1
Reported most in Body
Documents 42
Total Number 43
Disease Relevance 24.49
Pain Relevance 4.23

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytosol (HRAS) signal transduction (HRAS) Golgi apparatus (HRAS)
plasma membrane (HRAS) nucleus (HRAS) GTPase activity (HRAS)
Anatomy Link Frequency
skin 3
sperm 2
plasma 1
duct 1
joint 1
HRAS (Homo sapiens)
HRAS - G12V (1)
Pain Link Frequency Relevance Heat
Osteoarthritis 159 99.96 Very High Very High Very High
Pain 77 99.64 Very High Very High Very High
headache 15 99.64 Very High Very High Very High
Chronic pancreatitis 13 99.52 Very High Very High Very High
Inflammation 98 98.16 Very High Very High Very High
Versed 3 96.92 Very High Very High Very High
Inflammatory response 3 94.92 High High
cINOD 42 91.44 High High
tolerance 4 87.88 High High
antagonist 22 87.24 High High
Disease Link Frequency Relevance Heat
Osteoarthritis 145 99.96 Very High Very High Very High
Injury 39 99.86 Very High Very High Very High
Pain 80 99.64 Very High Very High Very High
Headache 15 99.64 Very High Very High Very High
Pancreatitis 15 99.52 Very High Very High Very High
Ehlers-danlos Syndrome 15 99.48 Very High Very High Very High
Aging 125 99.46 Very High Very High Very High
Carcinoma 25 99.24 Very High Very High Very High
Targeted Disruption 1 99.24 Very High Very High Very High
Dizziness 3 99.20 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Serous cystadenoma and atypical acinar cell nodules did not react with the Ha-ras oncogene product, and ductal cells and acinar cells in normal pancreas showed lower immunoreactivity than other benign or malignant lesions.
Ha-ras oncogene product Neg (not) Binding (react) of in pancreas associated with malignant neoplastic disease and serous cystadenoma
1) Confidence 0.48 Published 1990 Journal Hum. Pathol. Section Abstract Doc Link 2161789 Disease Relevance 0.89 Pain Relevance 0.08
To test these ideas, we determined the expression of PRC1 complex proteins (Bmi1 and Ring1b) during pancreatic development and in pancreatic tissue from mouse models of disease: acute and chronic pancreatic injury, duct ligation, and in K-Ras(G12V) conditional knock-in and caerulein-treated K-Ras(G12V) mice.
K-Ras (G12V) Spec (determined) Binding (ligation) of in duct associated with targeted disruption, injury and disease
2) Confidence 0.36 Published 2009 Journal J. Pathol. Section Abstract Doc Link 19585519 Disease Relevance 1.29 Pain Relevance 0.15
We isolated plasma DNA from 21 pancreatic cancer patients using a simple and rapid extraction technique and detected K-ras alterations with a PCR assay and subsequent product sequencing.
K-ras Binding (alterations) of in plasma associated with pancreatic cancer
3) Confidence 0.36 Published 1998 Journal Clin. Cancer Res. Section Abstract Doc Link 9516910 Disease Relevance 0.47 Pain Relevance 0.06
This class includes ligands that bound at signaling complexes such as MDM2–p53, farnesyltransfrease–h-ras, and histone acetyltransferase–p53.
h-ras Binding (bound) of
4) Confidence 0.35 Published 2010 Journal PLoS Computational Biology Section Body Doc Link PMC2816688 Disease Relevance 0.09 Pain Relevance 0
Moreover, K-ras mutations at codons 13 and 61 were not recognized in the PPJ of any patient with either PC or CP.
K-ras Binding (recognized) of associated with pancreatic cancer and chronic pancreatitis
5) Confidence 0.35 Published 1993 Journal Jpn. J. Cancer Res. Section Abstract Doc Link 8407563 Disease Relevance 1.09 Pain Relevance 0.44
On the contrary, with at least some designs, HA coating seems to be a risk factor for cup revision both due to aseptic loosening and for any reason, when adjusting for other covariates.
HA Binding (coating) of
6) Confidence 0.22 Published 2010 Journal Acta Orthopaedica Section Body Doc Link PMC2856204 Disease Relevance 0.17 Pain Relevance 0
The study also investigates whether alterations of p21ras occur in K-ras mutation-negative cases by using immunohistochemical staining for K-, N- and H-ras.
p21ras Binding (alterations) of
7) Confidence 0.20 Published 1999 Journal Hum. Pathol. Section Abstract Doc Link 10374765 Disease Relevance 1.48 Pain Relevance 0.25
Notably, a previous observation of an inverse association of AD and use of H2RAs was also affirmed.
H2RAs Binding (association) of
8) Confidence 0.10 Published 2000 Journal Neurology Section Body Doc Link 10851364 Disease Relevance 0 Pain Relevance 0
K-ras mutation was recognized in 85% (57/67) of SCs and 73% (11/15) of DCs, and multiple K-ras mutations in 12% (8/67) of SCs and in 20% (3/15) of DCs.
K-ras mutation Binding (recognized) of associated with carcinoma
9) Confidence 0.09 Published 1999 Journal Jpn. J. Cancer Res. Section Abstract Doc Link 10543256 Disease Relevance 2.60 Pain Relevance 0.08
One prior study showed a strong association between use of H2RAs and reduced AD prevalence.
H2RAs Binding (association) of
10) Confidence 0.08 Published 2000 Journal Neurology Section Body Doc Link 10851364 Disease Relevance 0 Pain Relevance 0
The newer H2RAs, nizatidine and famotidine, seem not to be associated with significant drug interactions [48-50].


H2RAs Binding (associated) of
11) Confidence 0.08 Published 2005 Journal Crit Care Section Body Doc Link PMC1065099 Disease Relevance 0.91 Pain Relevance 0.26
The most common adverse effects associated with H2RAs include headaches, dizziness, diarrhoea, nausea and constipation [1].
H2RAs Binding (associated) of associated with constipation, diarrhoea, vomiting, dizziness and headache
12) Confidence 0.08 Published 2005 Journal Crit Care Section Body Doc Link PMC1065099 Disease Relevance 1.10 Pain Relevance 0.22
With respect to drug interactions, the H2RAs cimetidine and ranitidine have the drawback of a potent inhibitory effect on the cytochrome oxidase enzyme system [16].
H2RAs Binding (interactions) of
13) Confidence 0.06 Published 2005 Journal Crit Care Section Body Doc Link PMC1065099 Disease Relevance 0.89 Pain Relevance 0.26
Considering pain reduction in OA, viscosupplementation with hyaluronic acid (HA) has been shown to have beneficial effects on both pain and function in patients with knee OA [4].
HA Binding (viscosupplementation) of in knee associated with pain and osteoarthritis
14) Confidence 0.02 Published 2008 Journal BMC Musculoskelet Disord Section Body Doc Link PMC2553787 Disease Relevance 1.02 Pain Relevance 0.84
On the other hand, because HA degradation products may interact with various cells and initiate a program of gene expression leading to cell proliferation, migration, or activation [3,4,7], these products exhibit biological functions that are quite distinct from those of the native, high-molecular-weight polymer.
HA Binding (interact) of
15) Confidence 0.01 Published 2005 Journal Arthritis Res Ther Section Body Doc Link PMC1175024 Disease Relevance 0.05 Pain Relevance 0.03
Hylans have been reported to have improved viscoelastic properties and an increased duration within the joint, as a function of cross-linking.30 Hylan G-F 20 was the first, and remains the only, cross-linked HA available in the United States.2 Hylan G-F 20 consists of a combination of the fluid and gel forms at a 4:1 ratio.
HA Binding (linked) of in joint
16) Confidence 0.01 Published 2009 Journal Journal of pain research Section Body Doc Link PMC3004631 Disease Relevance 0.23 Pain Relevance 0.12
Because specimens were not heat-denatured and because primate sperm PH-20 has a HA binding domain that is distinct from the hyaluronidase domain [17,31], we hypothesized that the binding of high-molecular-weight HA molecules to the PH-20 molecules may hamper the protein's movement to its expected location.
HA Binding (binding) of in sperm
17) Confidence 0.01 Published 2005 Journal Arthritis Res Ther Section Body Doc Link PMC1175024 Disease Relevance 0 Pain Relevance 0
PH-20 generates a mixture of HA oligosaccharides and fragments that may interact with various cells and produce distinct and important biological effects quite different from those induced by the native, high-molecular-weight polymer.
HA Binding (interact) of
18) Confidence 0.01 Published 2005 Journal Arthritis Res Ther Section Body Doc Link PMC1175024 Disease Relevance 0.23 Pain Relevance 0.05
There is also strong evidence that, via CD44 and/or other cell surface receptors, many cell types can bind and internalize HA, a process that, because of steric inhibition, is dependent upon the size of both HA and HA-bound macromolecules [40,41].
HA Binding (bind) of
19) Confidence 0.01 Published 2005 Journal Arthritis Res Ther Section Body Doc Link PMC1175024 Disease Relevance 0 Pain Relevance 0
First, by interacting with transmembrane proteins, such as CD44 and other members of the heterogeneous group of proteins termed hyaladherins, HA initiates signaling pathways and contributes to the formation of the pericellular matrix that prevents direct contact between cells and protects them against attack from viruses, bacteria, and immune cells.
HA Binding (interacting) of in immune cells
20) Confidence 0.01 Published 2005 Journal Arthritis Res Ther Section Body Doc Link PMC1175024 Disease Relevance 0.09 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox